Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients

References

• Borghi C, Dormi A, L'Italien G, et al. The relationship between systolic blood pressure and cardiovascular risk – results of the Brisighella Heart Study. J Clin Hypertens (Greenwich) 2003;V:47–521. Borghi C, Dormi A, L'Italien G, et al. The relationship between systolic blood pressure and cardiovascular risk – results of the Brisighella Heart Study. J Clin Hypertens (Greenwich) 2003;V:47–52
   Google Scholar
• Neal B, MacMahon S, Chapman N, et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955–642. Neal B, MacMahon S, Chapman N, et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955–64
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410–93. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410–9
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–524. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–52
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–875. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–87
   PubMed Web of Science ®Google Scholar
• Whitworth JA. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983–926. Whitworth JA. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983–92
   PubMed Web of Science ®Google Scholar
• Hajjar I, Kotchen TA. Trends in the prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. J Am Med Assoc 2003;290:199–2067. Hajjar I, Kotchen TA. Trends in the prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. J Am Med Assoc 2003;290:199–206
   PubMed Web of Science ®Google Scholar
• Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003;163:525–418. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003;163:525–41
   PubMed Web of Science ®Google Scholar
• Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36:646–619. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36:646–61
   Google Scholar
• Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. J Am Med Assoc 2003;289:2073–8210. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. J Am Med Assoc 2003;289:2073–82
   PubMed Web of Science ®Google Scholar
• Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002;4:393–40411. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002;4:393–404
   PubMedGoogle Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE). A randomized trial against atenolol. Lancet 2002;359:995–100312. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE). A randomized trial against atenolol. Lancet 2002;359:995–1003
   PubMed Web of Science ®Google Scholar
• Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23 Suppl 2:B54–6413. Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23 Suppl 2:B54–64
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755–6214. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755–62
   PubMed Web of Science ®Google Scholar
• Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites [Modification of Diet in Renal Disease Study Group]. Hypertension 1997;30:428–3515. Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites [Modification of Diet in Renal Disease Study Group]. Hypertension 1997;30:428–35
   PubMed Web of Science ®Google Scholar
• Neutel J, Smith D, Weber M, et al. Use of olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004;6:168–7416. Neutel J, Smith D, Weber M, et al. Use of olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004;6:168–74
   PubMedGoogle Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. J Am Med Assoc 2003;290:2805–1617. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. J Am Med Assoc 2003;290:2805–16
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703–1318. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703–13
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. J Am Med Assoc 2002;288:2421–3119. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. J Am Med Assoc 2002;288:2421–31
   PubMed Web of Science ®Google Scholar
• Wright JTJ, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002;162:1636–4320. Wright JTJ, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002;162:1636–43
   PubMed Web of Science ®Google Scholar
• Giunti S, Cooper M. Management strategies for patients with hypertension and diabetes: why combination therapy is critical. J Clin Hypertens (Greenwich) 2006;8:108–1321. Giunti S, Cooper M. Management strategies for patients with hypertension and diabetes: why combination therapy is critical. J Clin Hypertens (Greenwich) 2006;8:108–13
   PubMedGoogle Scholar
• Fretheim A, Oxman AD. International variation in prescribing antihypertensive drugs: its extent and possible explanations. BMC Health Serv Res 2005;5:2122. Fretheim A, Oxman AD. International variation in prescribing antihypertensive drugs: its extent and possible explanations. BMC Health Serv Res 2005;5:21
   PubMed Web of Science ®Google Scholar
• Stafford RS, Furberg CD, Finkelstein SN, et al. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996–2002. J Am Med Assoc 2004;291:54–6223. Stafford RS, Furberg CD, Finkelstein SN, et al. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996–2002. J Am Med Assoc 2004;291:54–62
   PubMed Web of Science ®Google Scholar
• Xie F, Petitti DB, Handler J. Changes in the continuation of antihypertensive drug use after ALLHAT. J Clin Hypertens (Greenwich) 2005;7:649–5324. Xie F, Petitti DB, Handler J. Changes in the continuation of antihypertensive drug use after ALLHAT. J Clin Hypertens (Greenwich) 2005;7:649–53
   PubMedGoogle Scholar
• Austin PC, Mamdani MM, Tu K, et al. Changes in prescribing patterns following publication of the ALLHAT trial. J Am Med Assoc 2004;291:44–525. Austin PC, Mamdani MM, Tu K, et al. Changes in prescribing patterns following publication of the ALLHAT trial. J Am Med Assoc 2004;291:44–5
   Web of Science ®Google Scholar
• Gu Q, Paulose-Ram R, Dillon C, et al. Antihypertensive medication use among US adults with hypertension. Circulation 2006;113:213–2126. Gu Q, Paulose-Ram R, Dillon C, et al. Antihypertensive medication use among US adults with hypertension. Circulation 2006;113:213–21
   PubMed Web of Science ®Google Scholar
• Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94 492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254–6227. Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94 492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254–62
   PubMed Web of Science ®Google Scholar
• Mayor S. NICE removes beta blockers as first line treatment for hypertension. Br Med J 2006;333:828. Mayor S. NICE removes beta blockers as first line treatment for hypertension. Br Med J 2006;333:8
   PubMed Web of Science ®Google Scholar
• Lopez J, Meier J, Cunningham F, et al. Antihypertensive medication use in the department of veterans affairs: a national analysis of prescribing patterns from 2000 to 2002. Am J Hypertens 2004;17:1095–929. Lopez J, Meier J, Cunningham F, et al. Antihypertensive medication use in the department of veterans affairs: a national analysis of prescribing patterns from 2000 to 2002. Am J Hypertens 2004;17:1095–9
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. J Am Med Assoc 2005;294:466–7230. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. J Am Med Assoc 2005;294:466–72
   PubMed Web of Science ®Google Scholar
• Cheung BM, Ong KL, Man YB. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001–2002. J Clin Hypertens (Greenwich) 2006;8:93–831. Cheung BM, Ong KL, Man YB. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001–2002. J Clin Hypertens (Greenwich) 2006;8:93–8
   PubMedGoogle Scholar
• Cheung BMY, Ong K, Wong LYF, et al. Prevalence, awareness, treatment, and control of hypertension in the United States 1999–2004. [abstract]. Circulation 2006;114 18:II_867–c32. Cheung BMY, Ong K, Wong LYF, et al. Prevalence, awareness, treatment, and control of hypertension in the United States 1999–2004. [abstract]. Circulation 2006;114 18:II_867–c
   Web of Science ®Google Scholar
• Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 2001;161:1207–1633. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 2001;161:1207–16
   PubMed Web of Science ®Google Scholar
• Hertz RP, Unger AN, Cornell JA, et al. Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med 2005;165:2098–10434. Hertz RP, Unger AN, Cornell JA, et al. Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med 2005;165:2098–104
   PubMed Web of Science ®Google Scholar
• Hicks LS, Fairchild DG, Horng MS, et al. Determinants of JNC VI guideline adherence, intensity of drug therapy, and blood pressure control by race and ethnicity. Hypertension 2004;44:429–3435. Hicks LS, Fairchild DG, Horng MS, et al. Determinants of JNC VI guideline adherence, intensity of drug therapy, and blood pressure control by race and ethnicity. Hypertension 2004;44:429–34
   PubMed Web of Science ®Google Scholar
• Howard G, Prineas R, Moy C, et al. Racial and geographic differences in awareness, treatment, and control of hypertension: the REasons for Geographic And Racial Differences in Stroke study. Stroke 2006;37:1171–836. Howard G, Prineas R, Moy C, et al. Racial and geographic differences in awareness, treatment, and control of hypertension: the REasons for Geographic And Racial Differences in Stroke study. Stroke 2006;37:1171–8
   PubMed Web of Science ®Google Scholar
• Maahs DM, Kinney GL, Wadwa P, et al. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care 2005;28:301–637. Maahs DM, Kinney GL, Wadwa P, et al. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care 2005;28:301–6
   PubMed Web of Science ®Google Scholar
• Schaars CF, Denig P, Kasje WN, et al. Physician, organizational, and patient factors associated with suboptimal blood pressure management in type 2 diabetic patients in primary care. Diabetes Care 2004;27:123–838. Schaars CF, Denig P, Kasje WN, et al. Physician, organizational, and patient factors associated with suboptimal blood pressure management in type 2 diabetic patients in primary care. Diabetes Care 2004;27:123–8
   PubMed Web of Science ®Google Scholar
• Candesartan New Drug Application. Medical review/statistical review. Study EC403. Dose-finding study of candesartan cilexetil/HCTZ combination (2, 4, 8, 16 mg for candesartan; 12/5, 25 mg for HCTZ) in patients with mild to moderate essential hypertension. Report No.: 21-09339. Candesartan New Drug Application. Medical review/statistical review. Study EC403. Dose-finding study of candesartan cilexetil/HCTZ combination (2, 4, 8, 16 mg for candesartan; 12/5, 25 mg for HCTZ) in patients with mild to moderate essential hypertension. Report No.: 21-093
   Google Scholar
• Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians. Arch Intern Med 2000;160:2281–640. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians. Arch Intern Med 2000;160:2281–6
   PubMed Web of Science ®Google Scholar
• Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. New Engl J Med 2001;345:479–8641. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. New Engl J Med 2001;345:479–86
   PubMed Web of Science ®Google Scholar
• Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162:413–2042. Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162:413–20
   PubMed Web of Science ®Google Scholar
• Berlowitz DR, Ash AS, Hickey EC, et al. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care 2003;26:355–943. Berlowitz DR, Ash AS, Hickey EC, et al. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care 2003;26:355–9
   PubMed Web of Science ®Google Scholar
• Psaty BM, Manolio TA, Smith NL, et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch Intern Med 2002;162:2325–3244. Psaty BM, Manolio TA, Smith NL, et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch Intern Med 2002;162:2325–32
   PubMed Web of Science ®Google Scholar
• Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. New Engl J Med 1998;339:1957–6345. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. New Engl J Med 1998;339:1957–63
   PubMed Web of Science ®Google Scholar
• Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006;47:345–5146. Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006;47:345–51
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New Engl J Med 2000;342:145–5347. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New Engl J Med 2000;342:145–53
   PubMed Web of Science ®Google Scholar
• Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. New Engl J Med 2003;348:583–9248. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. New Engl J Med 2003;348:583–92
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 1991;265:3255–6449. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 1991;265:3255–64
   PubMed Web of Science ®Google Scholar
• Ekbom T, Linjer E, Hedner T, et al. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2. Blood Press 2004;13:137–4150. Ekbom T, Linjer E, Hedner T, et al. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2. Blood Press 2004;13:137–41
   PubMed Web of Science ®Google Scholar
• Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol 2004;43:1047–5551. Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol 2004;43:1047–55
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension [The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators]. Lancet 1997;350:757–6452. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension [The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators]. Lancet 1997;350:757–64
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. J Am Med Assoc 2005;293:1595–60853. Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. J Am Med Assoc 2005;293:1595–608
   PubMed Web of Science ®Google Scholar
• Brewster LM, Van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004;141:614–2754. Brewster LM, Van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004;141:614–27
   PubMed Web of Science ®Google Scholar
• Leenen FH, Nwachuku C, Cushman WC, et al. Outcomes in high risk hypertensives randomized to CCB vs ACE inhibitor in ALLHAT. Am J Hypertens 2005;[Suppl 1]:A755. Leenen FH, Nwachuku C, Cushman WC, et al. Outcomes in high risk hypertensives randomized to CCB vs ACE inhibitor in ALLHAT. Am J Hypertens 2005;[Suppl 1]:A7
   Google Scholar
• Thornley-Brown D, Wang X, Wright JT Jr, et al. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Arch Intern Med 2006;166:797–80556. Thornley-Brown D, Wang X, Wright JT Jr, et al. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Arch Intern Med 2006;166:797–805
   PubMed Web of Science ®Google Scholar
• Gryglewska B. How can we improve the effectiveness of treatment in elderly hypertensives?. Blood Press 2005;2 Suppl:46–957. Gryglewska B. How can we improve the effectiveness of treatment in elderly hypertensives?. Blood Press 2005;2 Suppl:46–9
   Google Scholar
• Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996;156:1969–7858. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996;156:1969–78
   PubMed Web of Science ®Google Scholar
• Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994;154:1461–859. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994;154:1461–8
   PubMed Web of Science ®Google Scholar
• Gradman AH, Cutler NR, Davis PJ, et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension [Enalapril-Felodipine ER Factorial Study Group]. Am J Cardiol 1997;79:431–560. Gradman AH, Cutler NR, Davis PJ, et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension [Enalapril-Felodipine ER Factorial Study Group]. Am J Cardiol 1997;79:431–5
   PubMed Web of Science ®Google Scholar
• MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996;156:278–8561. MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996;156:278–85
   PubMed Web of Science ®Google Scholar
• Neutel JM, Saunders E, Bakris GL, et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005;7:578–8662. Neutel JM, Saunders E, Bakris GL, et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005;7:578–86
   PubMedGoogle Scholar
• Ofili EO, Ferdinand KC, Saunders E, et al. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc 2006;98:618–2663. Ofili EO, Ferdinand KC, Saunders E, et al. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc 2006;98:618–26
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004;17:252–964. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004;17:252–9
   PubMed Web of Science ®Google Scholar
• Salerno CM, Demopoulos L, Mukherjee R, et al. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich) 2004;6:614–2065. Salerno CM, Demopoulos L, Mukherjee R, et al. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich) 2004;6:614–20
   PubMedGoogle Scholar
• Lacourciere Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005;27:1013–2166. Lacourciere Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005;27:1013–21
   PubMed Web of Science ®Google Scholar
• Izzo JL Jr, Neutel JM, Silfani T, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich) 2007;9:36–4467. Izzo JL Jr, Neutel JM, Silfani T, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich) 2007;9:36–44
   PubMedGoogle Scholar
• Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004;17:495–50168. Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004;17:495–501
   PubMed Web of Science ®Google Scholar
• Scholze J, Bida M, Hansen A, et al. Initiation of hypertension treatment with a fixed-dose combination or its monocomponents – does it really matter? Int J Clin Pract 2006;60:265–7469. Scholze J, Bida M, Hansen A, et al. Initiation of hypertension treatment with a fixed-dose combination or its monocomponents – does it really matter? Int J Clin Pract 2006;60:265–74
   Google Scholar
• Neutel JM, Smith DH, Weber MA, et al. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich) 2005;7:641–670. Neutel JM, Smith DH, Weber MA, et al. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich) 2005;7:641–6
   PubMedGoogle Scholar
• Frishman WH, Ram CV, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study [The Benazepril/Amlodipine Study Group]. J Clin Pharmacol 1995;35:1060–671. Frishman WH, Ram CV, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study [The Benazepril/Amlodipine Study Group]. J Clin Pharmacol 1995;35:1060–6
   PubMed Web of Science ®Google Scholar
• Kuschnir E, Acuna E, Sevilla D, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther 1996;18:1213–2472. Kuschnir E, Acuna E, Sevilla D, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther 1996;18:1213–24
   PubMed Web of Science ®Google Scholar
• Pool J, Kaihlanen P, Lewis G, et al. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens 2001;15:495–873. Pool J, Kaihlanen P, Lewis G, et al. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens 2001;15:495–8
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003;326:1427–3474. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003;326:1427–34
   PubMed Web of Science ®Google Scholar
• Hasebe N, Kikuchi K. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005;23:445–5375. Hasebe N, Kikuchi K. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005;23:445–53
   PubMed Web of Science ®Google Scholar
• Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens 2002;15:544–976. Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens 2002;15:544–9
   PubMed Web of Science ®Google Scholar
• Dahlof B, Gosse P, Gueret P, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23:2063–7077. Dahlof B, Gosse P, Gueret P, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23:2063–70
   PubMed Web of Science ®Google Scholar
• de Luca N, Mallion JM, O'Rourke MF, et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004;17:660–778. de Luca N, Mallion JM, O'Rourke MF, et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004;17:660–7
   PubMed Web of Science ®Google Scholar
• Flack JM, Saunders E, Gradman A, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in African Americans with mild to moderate hypertension. Clin Ther 2001;23:1193–20879. Flack JM, Saunders E, Gradman A, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in African Americans with mild to moderate hypertension. Clin Ther 2001;23:1193–208
   PubMed Web of Science ®Google Scholar
• McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001;23:833–5080. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001;23:833–50
   PubMed Web of Science ®Google Scholar
• Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens 2002;15:550–681. Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens 2002;15:550–6
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS, Plosker GL. Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension. Drugs 2005;65:1851–6882. Cvetkovic RS, Plosker GL. Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension. Drugs 2005;65:1851–68
   PubMed Web of Science ®Google Scholar
• Reynolds NA, Wagstaff AJ, Keam SJ. Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. Drugs 2005;65:1893–91483. Reynolds NA, Wagstaff AJ, Keam SJ. Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. Drugs 2005;65:1893–914
   PubMed Web of Science ®Google Scholar
• Chalmers J, Castaigne A, Morgan T, et al. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens 2000;18:327–3784. Chalmers J, Castaigne A, Morgan T, et al. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens 2000;18:327–37
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–90685. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906
   PubMed Web of Science ®Google Scholar
• Ofili EO. Dispelling the myth of ‘aggressive’ antihypertensive therapy. J Clin Hypertens (Greenwich) 2006;8:4–1186. Ofili EO. Dispelling the myth of ‘aggressive’ antihypertensive therapy. J Clin Hypertens (Greenwich) 2006;8:4–11
   PubMedGoogle Scholar
• Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Can Med Assoc J 1999;160:41–687. Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Can Med Assoc J 1999;160:41–6
   PubMed Web of Science ®Google Scholar
• Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443–6288. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443–62
   PubMed Web of Science ®Google Scholar
• Giles TD. Rationale for combination therapy as initial treatment for hypertension. J Clin Hypertens (Greenwich) 2003;5:4–1189. Giles TD. Rationale for combination therapy as initial treatment for hypertension. J Clin Hypertens (Greenwich) 2003;5:4–11
   PubMedGoogle Scholar
• Neutel JM, Smith DH, Weber MA. Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens 2001;14:286–9290. Neutel JM, Smith DH, Weber MA. Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens 2001;14:286–92
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004–1091. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004–10
   PubMed Web of Science ®Google Scholar
• Stump CS, Sowers JR. Prevention of type 2 diabetes: role of the renin-angiotensin-aldosterone system and antihypertensive therapy. Advanced Studies in Medicine 2006;6:231–992. Stump CS, Sowers JR. Prevention of type 2 diabetes: role of the renin-angiotensin-aldosterone system and antihypertensive therapy. Advanced Studies in Medicine 2006;6:231–9
   Google Scholar
• Chrysant SG. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J Hum Hypertens 2005;19:923–3193. Chrysant SG. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J Hum Hypertens 2005;19:923–31
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today (Barc) 2004;40:791–80194. Chrysant SG. Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today (Barc) 2004;40:791–801
   PubMed Web of Science ®Google Scholar
• Sica DA. Calcium channel blocker-related peripheral edema: can it be resolved? J Clin Hypertens (Greenwich) 2003;5:291–4 , 29795. Sica DA. Calcium channel blocker-related peripheral edema: can it be resolved? J Clin Hypertens (Greenwich) 2003;5:291–4, 297
   PubMedGoogle Scholar
• See S. Angiotensin II receptor blockers for the treatment of hypertension. Expert Opin Pharmacother 2001;2:1795–80496. See S. Angiotensin II receptor blockers for the treatment of hypertension. Expert Opin Pharmacother 2001;2:1795–804
   PubMedGoogle Scholar
• Kohlmann O Jr, Oigman W, Mion D Jr, et al. The ‘LOTHAR’ study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension. Arq Bras Cardiol 2006;86:39–5197. Kohlmann O Jr, Oigman W, Mion D Jr, et al. The ‘LOTHAR’ study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension. Arq Bras Cardiol 2006;86:39–51
   PubMedGoogle Scholar
• Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563–8098. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563–80
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587–60499. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587–604
   PubMed Web of Science ®Google Scholar